{"entity":{"id":"nct05584670","kind":"trial","name":"A First-in-human, Dose Escalation and Dose Expansion Study of SAR445877 in Adult Participants With Advanced Solid Tumors","aka":[],"tldr":"A phase 1/2 trial of Cetuximab, ADG126, Bevacizumab, Nivolumab and Ipilimumab in advanced solid tumours, run by Sanofi, now recruiting.","summary":"A First-in-human, Dose Escalation and Dose Expansion Study of SAR445877 in Adult Participants With Advanced Solid Tumors is a phase 1/2 interventional study registered as NCT05584670 by Sanofi, with 542 participants planned, started 2022-11-29 and due to reach its primary completion in 2027-01-19. Interventions recorded: SAR445877, Cetuximab, ADG126, Bevacizumab, Nivolumab and Ipilimumab.","status":"recruiting","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT05584670","url":"https://clinicaltrials.gov/study/NCT05584670"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["metastatic-cancer"],"sections":[],"technologies":[],"targets":[],"drugs":["cetuximab","adg126","bevacizumab","nivolumab","ipilimumab"],"companies":["sanofi"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT05584670","phase":"1/2","setting":"A Phase 1/2, Open Label, First-in-human, Dose Escalation and Expansion Study for the Evaluation of Safety, Pharmacokinetics, Pharmacodynamics, and Anti-tumor Activity of SAR445877 Administered as Monotherapy or in Combination With Other Anticancer Therapies in Adults With Advanced Solid Tumors","sponsor":"Sanofi","participation":[{"nct":"NCT05584670","source":"https://clinicaltrials.gov/study/NCT05584670","fetchedAt":"2026-10-07T16:53:46.156Z","studySha256":"55d24e4c91b2dd3836ebe80ddb8b334789201119bd67c4ec7e0af31d88573b96","overallStatus":"RECRUITING","lastUpdatePosted":"2026-06-23","leadSponsor":"Sanofi","collaboratorCount":0,"minimumAge":"18 Years","sex":"ALL","healthyVolunteers":false,"hasEligibility":true,"enrolment":542,"enrolmentType":"ESTIMATED","siteCount":22,"recruitingSiteCount":21,"countries":["Chile","Israel","Japan","Netherlands","Spain","United States"]}],"started":"2022-11-29","startedType":"actual","enrolled":542,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct05584670/","neighbours":{"cancer":[{"id":"metastatic-cancer","kind":"cancer","name":"Metastatic cancer (cancer that has spread)","route":"/cancers/metastatic-cancer/"}],"drug":[{"id":"adg126","kind":"drug","name":"ADG126","route":"/drugs/adg126/"},{"id":"bevacizumab","kind":"drug","name":"Bevacizumab","route":"/drugs/bevacizumab/"},{"id":"cetuximab","kind":"drug","name":"Cetuximab","route":"/drugs/cetuximab/"},{"id":"ipilimumab","kind":"drug","name":"Ipilimumab","route":"/drugs/ipilimumab/"},{"id":"nivolumab","kind":"drug","name":"Nivolumab","route":"/drugs/nivolumab/"}],"company":[{"id":"sanofi","kind":"company","name":"Sanofi","route":"/companies/sanofi/"}]}}